The Tortoise and the Hare: Wellpoint Slowly Gains on Part D Leaders
This article was originally published in RPM Report
Executive Summary
Wellpoint is not one of the most aggressive players in the Medicare market, but it will be gaining the most new enrollees in 2008. Does slow and steady win this race?
You may also be interested in...
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.